Feature Channels:

Article ID: 720620

A new paper published in the October 17 2019 issue of Clinical Infectious Diseases reiterates the need to stop the infection and defines a strategy for developing effective vaccines.

Article ID: 720756

In a study using non-invasive tape strips in young children with eczema (or atopic dermatitis), researchers found many molecular signs of immune dysfunction and skin changes that relate to disease activity. These signs (or biomarkers) were present even before eczema was visible and can be used to track disease activity over time. With more research, these biomarkers also may help predict response to medicine and development of conditions associated with eczema, such as asthma, other allergies, infections and even attention deficit hyperactivity disorder (ADHD). Findings were published in JAMA Dermatology.

Article ID: 720681

This fall, a group of skin cancer advocates and their families and friends in both Chicago and Phoenix hiked three miles to say “Skin Cancer, Take a Hike!” Together, they raised nearly $40,000 for SPOT Skin Cancer™ benefiting the American Academy of Dermatology’s skin cancer prevention and detection programs, including free skin cancer screenings, sunscreen dispensers, and permanent shade structures in outdoor spaces where children learn and play.

Article ID: 720595

Current testing for Lyme disease, called the standard 2-tiered approach or the STT, involves running two complex assays (ELISA and western blot) to detect antibodies against the bacterium, and requires experienced personnel in a lab, and a few hours to carry out and interpret. Columbia biomedical engineers have developed a rapid microfluidic test that can detect Lyme disease with similar performance as the STT in a much shorter time—15 minutes.

Article ID: 720348

A new study led by UCLA researchers, have found that obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology can help improve the accuracy and reliability of diagnosing melanoma, one of the deadliest and most aggressive forms of skin cancer.

Article ID: 720513

Atopic dermatitis (also known as eczema) is a common skin condition in babies. It affects up to 25% of children, and an estimated 60% of people with eczema develop it during their first year of life. While there is no cure, dermatologists from the American Academy of Dermatology say most cases can be controlled with a customized skin care plan, which may include moisturizers, prescription medications and strategies to eliminate triggers.

Article ID: 720321

May also help predict therapeutic responses

Article ID: 720442

To conduct preclinical testing of locally-acting topical dermal and ophthalmic drug product formulations

Article ID: 720364

In a new study published in EBioMedicine, researchers with Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence reveal that differences at the single-cell level can predict responses to initial BRAF inhibitor therapy, and that leveraging these differences may improve patient outcomes.